SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Boni, V.; Alemany, C.; Meisel, J. L.; Sinha, R.; Sterrenberg, D.; Tkaczuk, K. H. R.; Wang, Y.; Wang, Z.; Han, H. S.

authors

Publication Date

  • May 1, 2019

webpage

published in

category

volume

  • 30